Connect with us

Hi, what are you looking for?

World

WHO experts voice “very low confidence” in some Sinopharm COVID-19 vaccine data

WHO experts have voiced “very low confidence” in data provided by Chinese state-owned drugmaker Sinopharm on its COVID-19 vaccine regarding the risk of serious side-effects in some patients, but overall confidence in its ability to prevent the disease, a document seen by Reuters shows.

For the latest headlines, follow our Google News channel online or via the app.

There was no immediate reply from the World Health Organization to a query about any concerns linked to the Sinopharm vaccine, BBIBP-CorV. In Beijing, Sinopharm was not immediately reachable for comment outside working hours.

The “evidence assessment” document was prepared by the WHO’s Strategic Advisory Group of Experts (SAGE) for its review scheduled this week of the Sinopharm shot, authorized by 45 countries and jurisdictions for use in adults, with 65 million doses administered. The experts review evidence and give recommendations on policy and dosages associated with a vaccine.

The document includes summaries of data from clinical trials in China, Bahrain, Egypt, Jordan and the United Arab Emirates.

Vaccine efficacy in multi-country Phase 3 clinical trials was 78.1 percent after two doses, the document said. This was a slight drop from 79.34 percent announced previously in China.

“We are very confident that 2 doses of BBIBP-CorV are efficacious in preventing PCR confirmed COVID19 in adults (18-59 years),” the document said.

But it added: “Analysis of safety amongst participants with comorbidities (was) limited by the low number of participants with comorbidities (other than obesity) in the Phase 3 trial.”

Among “evidence gaps”, it cited data on protection against severe disease, duration of protection, safety for use in pregnant women and in older adults and identification/evaluation of rare adverse events through post-authorization safety monitoring.

“We have very low confidence in the quality of evidence that the risk of serious adverse events following one or two doses of BBIBP-CorV in older adults (≥60 years) is low,” it said.

“We have very low confidence in the quality of evidence that the risk of serious adverse events in individuals with comorbidities or health states that increase risk for severe COVID-19 following one or two doses of BBIBP-CorV is low,” it added.

The SAGE analysis was prepared as a WHO technical advisory group currently reviews the vaccine for an emergency use approval, which would not only pave the way for its use in the global COVAX vaccine sharing platform but also provide a crucial international endorsement for a vaccine developed in China.

A WHO spokesman said that a decision on the listing was not expected on Wednesday.

Next articles

No one who received Sinopharm vaccine doses has died of COVID-19 in Abu Dhabi: Study

UAE firm to start producing China’s Sinopharm COVID-19 vaccine after deal

New Abu Dhabi plant to make COVID-19 vaccine from China’s Sinopharm

 

 

You May Also Like

World

Sitting by herself at the funeral of Prince Philip on Saturday, Queen Elizabeth cut a regal, but solitary figure: still the monarch, but now...

World

Germany’s vaccine commission, known as STIKO, recommended on Thursday that people under 60-years old who have had a first shot of AstraZeneca’s COVID-19 vaccine...

World

Activists opposed to Myanmar’s junta called on Monday for people to stop paying electricity bills and agricultural loans, and keep their children away from...

Life Style

An uncrewed SpaceX Starship prototype rocket failed to land safely on Tuesday after a test launch from Boca Chica, Texas, and engineers were investigating,...

Advertisement

error: